Antiphospholipid Syndrome

Establish APS when at least one clinical criterion coexists with at least one persistently positive antiphospholipid antibody. Qualifying clinical phenotypes include arterial, venous, or microvascular thrombosis and pregnancy morbidity; laboratory persistence requires repeat positivity at a minimum interval of 12 weeks.Wiley+2WileyDesign and Implementation of an Automated Interpretation Algorithm for Lupus Anticoagulant Functional TestingWileyBritish Journal of HaematologyWileyGuidelines on the investigation and management ...

Order all three laboratory domains rather than relying on a single assay: phospholipid-dependent coagulation testing for lupus anticoagulant (LA), anticardiolipin antibody immunoassays, and anti-beta-2-glycoprotein I antibody immunoassays. LA testing is the most technically complex component and can be confounded by anticoagulant therapy or factor deficiency patterns in mixing studies.WileyWileyDesign and Implementation of an Automated Interpretation Algorithm for Lupus Anticoagulant Functional Testing

Treat a first positive LA result as provisional. Repeat LA testing after 12 weeks, and apply the same persistence principle to other antiphospholipid antibody results before labeling APS outside an immediately life-threatening thrombotic presentation.Wiley+2WileyDesign and Implementation of an Automated Interpretation Algorithm for Lupus Anticoagulant Functional TestingWileyAntiphospholipid antibody testing and standardizationWileyBritish Journal of Haematology

Suspect catastrophic APS (CAPS) when thromboses affect three or more organ systems simultaneously or within less than 1 week, particularly with histopathologic small-vessel occlusion and antiphospholipid antibody positivity. Thrombocytopenia may accompany CAPS and can resemble heparin-induced thrombocytopenia or disseminated intravascular coagulation.Wolters KluwerWolters KluwerISPRM 2020 : The Journal of the International Society ...

For suspected CAPS, obtain urgent imaging directed by organ ischemia, document thrombosis across involved vascular beds, and seek tissue confirmation of small-vessel occlusion when a safely accessible involved site exists. Coordinate hematology, rheumatology, critical care, and the relevant organ specialty while treating active thrombosis and evaluating competing diagnoses.Wolters KluwerWolters KluwerISPRM 2020 : The Journal of the International Society ...

Pregnancy is a recognized CAPS-associated setting: 8% of 500 CAPS Registry cases occurred in association with pregnancy. Escalate immediately when a pregnant or postpartum patient has concurrent thrombosis, thrombocytopenia, organ dysfunction, or rapidly evolving ischemic symptoms.PubMedPubMedWarfarin and heparin monitoring in antiphospholipid syndrome

For thrombotic APS, use a vitamin K antagonist (VKA), preferably warfarin, as long-term secondary prevention. Current evidence-based guidance supports lifelong VKA therapy in thrombotic APS, with low-molecular-weight heparin or unfractionated heparin used in selected situations.PubMed+1PubMedManagement of Antiphospholipid SyndromePubMedWarfarin and heparin monitoring in antiphospholipid syndrome

For prior arterial thrombosis, do not use low-dose aspirin alone when APS is definite; VKA therapy is recommended over aspirin monotherapy.BMJBMJEULAR recommendations for the management ... Anticoagulation intensity remains clinically consequential: available strategies include warfarin with target INR 3.0-4.0 or warfarin with INR 2.0-3.0 plus low-dose aspirin. Select between them according to recurrent arterial thrombosis risk, prior bleeding, thrombocytopenia, and feasibility of stable INR monitoring.PubMed+1PubMedManagement of Antiphospholipid SyndromePubMedWarfarin and heparin monitoring in antiphospholipid syndrome

For recurrent thrombosis during warfarin therapy, first determine whether recurrence occurred at therapeutic anticoagulation intensity. If recurrence occurs on standard-intensity warfarin, options include adding low-dose aspirin, increasing the target INR to 3.0-4.0, or changing to LMWH.PubMedPubMedWarfarin and heparin monitoring in antiphospholipid syndrome

Avoid DOACs in high-risk APS, especially triple-positive patients and those with previous arterial events. A randomized trial in triple-positive APS was stopped early because thromboembolic events, predominantly arterial events, were more frequent with rivaroxaban than warfarin.BMJ+1BMJEULAR recommendations for the management ...PubMedManagement of Antiphospholipid Syndrome Some guidance allows carefully selected patients with low-risk venous APS to remain on or consider a DOAC when warfarin is not feasible, but evidence is limited and this approach does not apply to arterial APS or triple positivity.PubMed+1PubMedManagement of Antiphospholipid SyndromePubMedUse of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines - PMC

For an asymptomatic individual with a persistent high-risk antiphospholipid antibody profile, low-dose aspirin is recommended for primary prophylaxis in the EULAR framework. High-risk status includes LA, double or triple positivity, or persistently high titers.NatureNatureAntiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study | Scientific Reports

The estimated thrombosis incidence in high-risk antibody profiles may be as high as 5% per person-year, supporting a distinct prevention discussion from that used for isolated low-risk antibody positivity.NatureNatureAntiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study | Scientific Reports Confirm persistence before committing to prophylaxis, and distinguish primary prevention from the lifelong VKA strategy used after documented thrombotic APS.Nature+1NatureAntiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study | Scientific ReportsPubMedManagement of Antiphospholipid Syndrome

Evaluate pregnancy morbidity for APS with LA, anticardiolipin, and anti-beta-2-glycoprotein I testing; one or more morphologically normal fetal losses after the 10th gestational week qualifies as an adverse pregnancy outcome in APS criteria.Wiley+1WileyDesign and Implementation of an Automated Interpretation Algorithm for Lupus Anticoagulant Functional TestingWileyTriage and care for women with symptoms or diagnosis of pregnancy loss between 14 + 0 and 21 + 6 weeks' gestation - Fox - 2026 - International Journal of Gynecology & Obstetrics - Wiley Online Library When testing follows pregnancy loss, repeat a positive LA or anticardiolipin result after a further 12 weeks to establish persistence.WileyWileyTriage and care for women with symptoms or diagnosis of pregnancy loss between 14 + 0 and 21 + 6 weeks' gestation - Fox - 2026 - International Journal of Gynecology & Obstetrics - Wiley Online Library

LA and anticardiolipin antibodies are associated with recurrent fetal loss. In meta-analysis, LA was associated with late recurrent fetal loss (odds ratio 7.79, 95% CI 2.30-26.45), and IgM anticardiolipin antibody with late recurrent fetal loss (odds ratio 5.61, 95% CI 1.26-25.03).WileyWileyTriage and care for women with symptoms or diagnosis of pregnancy loss between 14 + 0 and 21 + 6 weeks' gestation - Fox - 2026 - International Journal of Gynecology & Obstetrics - Wiley Online Library

For obstetric APS, use combination low-dose aspirin plus heparin as the conventional treatment strategy.PubMedPubMedManagement of Antiphospholipid Syndrome Do not substitute a DOAC for pregnancy-directed heparin-based therapy; DOAC evidence and guideline exceptions discussed for selected low-risk venous APS do not establish a role in obstetric APS.PubMed+1PubMedManagement of Antiphospholipid SyndromePubMedUse of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines - PMC